WEKO3
アイテム
{"_buckets": {"deposit": "09bad8f2-8b08-4005-b8af-36f28c31be3a"}, "_deposit": {"created_by": 2, "id": "14189", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "14189"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00014189", "sets": ["30"]}, "author_link": ["51201", "51202", "51197", "51196", "51195", "51198", "51194", "51200", "51193", "51199"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2010-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "9", "bibliographicPageEnd": "1409", "bibliographicPageStart": "1404", "bibliographicVolumeNumber": "5", "bibliographic_titles": [{"bibliographic_title": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "INTRODUCTION: We assessed the relationship between the plasma concentration of gefitinib and its efficacy in Japanese patients with advanced non-small cell lung cancer (NSCLC). METHODS: Plasma trough levels of gefitinib were measured on days 3 (D3) and 8 (D8) by high-performance liquid chromatography in 44 patients with advanced NSCLC treated with 250 mg gefitinib daily. Eligibility criteria included performance status \u003c or =3, age \u003c or = 80 years, and stages IIIB-IV cancer. Epidermal growth factor receptor mutations in 23 patients were analyzed retrospectively. RESULTS: The median plasma gefitinib values were 662 ng/ml on D3 and 1064 ng/ml on D8, and the D8/D3 ratio was 1.587. The median progression-free survival (PFS) was 71 days, and the median overall survival was 224 days. Adenocarcinoma, never smoking, and high D8/D3 ratio were associated with better PFS. Multivariate analysis showed that PFS was associated with never smoking and high D8/D3 ratio. Never-smokers with a high D8/D3 ratio showed the best PFS. Overall survival was not associated with the D8/D3 ratio. Epidermal growth factor receptor mutation analysis of 23 patients showed that 15 patients had exon 19 deletion and/or exon 21 point mutation. Median PFS was similar between mutation-positive and mutation-negative individuals in the high D8/D3 group, whereas mutation-negative individuals in the low D8/D3 group showed the worst median PFS. CONCLUSIONS: A high D8/D3 ratio was independently associated with better PFS in patients with NSCLC treated with gefitinib. Our findings suggest that the pharmacokinetics of gefitinib may be involved in its antitumor activity.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Journal of thoracic oncology, 5(9), pp.1404-1409; 2010", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "the International Association for the Study of Lung Cancer"}]}, "item_2_relation_11": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "20651613", "subitem_relation_type_select": "PMID"}}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1097/JTO.0b013e3181e59a7b", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2010 by the International Association for the Study of Lung Cancer."}, {"subitem_rights": "This is a non-final version of an article published in final form in Journal of thoracic oncology, 5(9), pp.1404-1409; 2010."}]}, "item_2_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA12058455", "subitem_source_identifier_type": "NCID"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "15560864", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nakamura, Yoichi"}], "nameIdentifiers": [{"nameIdentifier": "51193", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sano, Kazumi"}], "nameIdentifiers": [{"nameIdentifier": "51194", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Soda, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "51195", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takatani, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "51196", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukuda, Minoru"}], "nameIdentifiers": [{"nameIdentifier": "51197", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagashima, Seiji"}], "nameIdentifiers": [{"nameIdentifier": "51198", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hayashi, Tomayoshi"}], "nameIdentifiers": [{"nameIdentifier": "51199", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oka, Mikio"}], "nameIdentifiers": [{"nameIdentifier": "51200", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsukamoto, Kazuhiro"}], "nameIdentifiers": [{"nameIdentifier": "51201", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kohno, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "51202", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "JTO5_1404.pdf", "filesize": [{"value": "267.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 267200.0, "url": {"label": "JTO5_1404.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/14189/files/JTO5_1404.pdf"}, "version_id": "31fde9ed-4283-49c7-ade8-7a4578fe3dc0"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Chemotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "EGFR mutation", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Gefitinib", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Non-small cell lung cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Pharmacokinetics", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer."}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/25919", "pubdate": {"attribute_name": "公開日", "attribute_value": "2011-10-03"}, "publish_date": "2011-10-03", "publish_status": "0", "recid": "14189", "relation": {}, "relation_version_is_last": true, "title": ["Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer."], "weko_shared_id": -1}
Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer.
http://hdl.handle.net/10069/25919
http://hdl.handle.net/10069/2591985cda046-ab85-400f-b524-97bfa5ba523c
名前 / ファイル | ライセンス | アクション |
---|---|---|
JTO5_1404.pdf (267.2 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2011-10-03 | |||||
タイトル | ||||||
タイトル | Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Chemotherapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | EGFR mutation | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Gefitinib | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Non-small cell lung cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Pharmacokinetics | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Nakamura, Yoichi
× Nakamura, Yoichi× Sano, Kazumi× Soda, Hiroshi× Takatani, Hiroshi× Fukuda, Minoru× Nagashima, Seiji× Hayashi, Tomayoshi× Oka, Mikio× Tsukamoto, Kazuhiro× Kohno, Shigeru |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | INTRODUCTION: We assessed the relationship between the plasma concentration of gefitinib and its efficacy in Japanese patients with advanced non-small cell lung cancer (NSCLC). METHODS: Plasma trough levels of gefitinib were measured on days 3 (D3) and 8 (D8) by high-performance liquid chromatography in 44 patients with advanced NSCLC treated with 250 mg gefitinib daily. Eligibility criteria included performance status < or =3, age < or = 80 years, and stages IIIB-IV cancer. Epidermal growth factor receptor mutations in 23 patients were analyzed retrospectively. RESULTS: The median plasma gefitinib values were 662 ng/ml on D3 and 1064 ng/ml on D8, and the D8/D3 ratio was 1.587. The median progression-free survival (PFS) was 71 days, and the median overall survival was 224 days. Adenocarcinoma, never smoking, and high D8/D3 ratio were associated with better PFS. Multivariate analysis showed that PFS was associated with never smoking and high D8/D3 ratio. Never-smokers with a high D8/D3 ratio showed the best PFS. Overall survival was not associated with the D8/D3 ratio. Epidermal growth factor receptor mutation analysis of 23 patients showed that 15 patients had exon 19 deletion and/or exon 21 point mutation. Median PFS was similar between mutation-positive and mutation-negative individuals in the high D8/D3 group, whereas mutation-negative individuals in the low D8/D3 group showed the worst median PFS. CONCLUSIONS: A high D8/D3 ratio was independently associated with better PFS in patients with NSCLC treated with gefitinib. Our findings suggest that the pharmacokinetics of gefitinib may be involved in its antitumor activity. | |||||
書誌情報 |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 巻 5, 号 9, p. 1404-1409, 発行日 2010-09 |
|||||
出版者 | ||||||
出版者 | the International Association for the Study of Lung Cancer | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 15560864 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA12058455 | |||||
PubMed番号 | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | PMID | |||||
関連識別子 | 20651613 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1097/JTO.0b013e3181e59a7b | |||||
権利 | ||||||
権利情報 | © 2010 by the International Association for the Study of Lung Cancer. | |||||
権利 | ||||||
権利情報 | This is a non-final version of an article published in final form in Journal of thoracic oncology, 5(9), pp.1404-1409; 2010. | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Journal of thoracic oncology, 5(9), pp.1404-1409; 2010 |